Financials · GILD

Gilead Sciences Inc. (GILD) financials

For the twelve months ended Sep 30, 2026, Gilead Sciences Inc. reported $30.99B of revenue and -$3.86B of net income.

Revenue, TTM
$30.99B
Revenue growth, YoY
+6.5%
Net income, TTM
-$3.86B
Net margin
-12.5%
Free cash flow, TTM
$13.78B
EPS, diluted, TTM
-$3.15
Cash
$6.44B
Total debt
$26.23B
P/S
6.67
Market cap
$206.55B
Annual revenue$29.44B
FY2016FY2025
Annual net income$8.51B
FY2016FY2025
Annual free cash flow$9.46B
FY2016FY2025

GILD revenue and earnings growth

GILD revenueQ3 2026$8.30B

Quarter YoY
+6.8%
QoQ
+6.4%
FY YoY
+2.4%
5Y CAGR
+3.6%
10Y CAGR
-1.0%

GILD revenue was $8.30B in fiscal Q3 2026 (ended Sep 30, 2026), up 6.8% from a year earlier and up 6.4% from the prior quarter. For the full fiscal 2025 it was $29.44B, up 2.4% from fiscal 2024. Compound annual growth was +3.6% over 5 years and -1.0% over 10 years. It rose in 5 of the last 10 fiscal years.

GILD net incomeQ3 2026$2.43B

Quarter YoY
-20.4%
FY YoY
18x
5Y CAGR
+133.3%
10Y CAGR
-7.3%

GILD net income was $2.43B in fiscal Q3 2026 (ended Sep 30, 2026), down 20.4% from a year earlier. For the full fiscal 2025 it was $8.51B, up about 18-fold from fiscal 2024. Compound annual growth was +133.3% over 5 years and -7.3% over 10 years. It rose in 4 of the last 10 fiscal years.

GILD EPSQ3 2026$1.94

Quarter YoY
-20.2%
FY YoY
18x
5Y CAGR
+132.4%
10Y CAGR
-5.5%

GILD diluted EPS was $1.94 in fiscal Q3 2026 (ended Sep 30, 2026), down 20.2% from a year earlier. For the full fiscal 2025 it was $6.78, up about 18-fold from fiscal 2024. Compound annual growth was +132.4% over 5 years and -5.5% over 10 years.

GILD free cash flowQ3 2026$4.80B

Quarter YoY
+21.1%
QoQ
+39.8%
FY YoY
-8.2%
5Y CAGR
+4.7%
10Y CAGR
-7.4%

GILD free cash flow was $4.80B in fiscal Q3 2026 (ended Sep 30, 2026), up 21.1% from a year earlier and up 39.8% from the prior quarter. For the full fiscal 2025 it was $9.46B, down 8.2% from fiscal 2024. Compound annual growth was +4.7% over 5 years and -7.4% over 10 years. It rose in 3 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$29.44B$28.75B$27.12B$27.28B$27.30B$24.69B$22.45B$22.13B$26.11B$30.39B
Cost of revenue$6.23B$6.25B$6.50B$5.66B$6.60B$4.57B$4.67B$4.85B$4.37B$4.26B
Gross profit$23.21B$22.50B$20.62B$21.62B$20.70B$20.12B$17.77B$17.27B$21.74B$26.13B
Research and development$5.80B$5.91B$5.72B$4.98B$4.60B$4.93B$4.05B$3.92B$3.73B$5.10B
Selling, general and admin$5.77B$6.09B$6.09B$5.67B$5.25B$5.15B$4.38B$4.06B$3.88B$3.40B
Operating income$10.02B$1.66B$7.61B$7.33B$9.92B$4.07B$4.29B$8.20B$14.12B$17.63B
Interest expense$1.02B$977.00M$944.00M$935.00M$1.00B$984.00M$995.00M$1.08B$1.12B$964.00M
Pre-tax income$9.80B$690.00M$6.86B$5.81B$8.28B$1.67B$5.16B$7.80B$13.53B$17.10B
Income tax$1.29B$211.00M$1.25B$1.25B$2.08B$1.58B-$204.00M$2.34B$8.88B$3.61B
Net income$8.51B$480.00M$5.67B$4.59B$6.22B$123.00M$5.39B$5.46B$4.63B$13.50B
EPS, basic$6.84$0.38$4.54$3.66$4.96$0.10$4.24$4.20$3.54$10.08
EPS, diluted$6.78$0.38$4.50$3.64$4.93$0.10$4.22$4.17$3.51$9.94
Diluted shares1.25B1.25B1.26B1.26B1.26B1.26B1.28B1.31B1.32B1.36B

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$7.56B$9.99B$6.08B$5.41B$5.34B$6.00B$11.63B$17.94B$7.59B$8.23B
Short-term investments$68.00M$0$1.18B$973.00M$1.18B$1.41B$12.72B$12.15B$17.92B$3.67B
Receivables$4.91B$4.42B$4.66B$4.78B$4.49B$4.89B$3.58B$3.33B$3.85B$4.51B
Inventory$1.77B$1.71B$1.79B$1.51B$1.62B$1.68B$922.00M$814.00M$801.00M$1.59B
Current assets$18.34B$19.17B$16.09B$14.44B$14.77B$16.00B$30.30B$35.84B$31.82B$19.59B
Goodwill$8.31B$8.31B$8.31B$8.31B$8.33B$8.11B$4.12B$4.12B$4.16B$1.17B
Total assets$59.02B$58.99B$62.13B$63.17B$67.95B$68.41B$61.63B$63.67B$70.28B$56.98B
Current liabilities$11.81B$12.00B$11.28B$11.24B$11.61B$11.40B$9.76B$10.61B$11.63B$9.22B
Short-term debt$2.81B$1.81B$1.80B$2.27B$1.52B$2.76B$2.50B$2.75B$2.75B$0
Long-term debt$22.13B$24.90B$23.19B$22.96B$25.18B$28.64B$22.09B$24.57B$30.80B$26.35B
Total debt$24.94B$26.71B$24.99B$25.23B$26.70B$31.40B$24.59B$27.32B$33.54B$26.35B
Total liabilities$36.41B$39.75B$39.38B$41.96B$46.89B$50.19B$38.98B$42.14B$49.78B$37.61B
Shareholders' equity$22.70B$19.25B$22.75B$21.21B$21.06B$18.22B$22.65B$21.53B$20.50B$19.36B

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$10.02B$10.83B$8.01B$9.07B$11.38B$8.17B$9.14B$8.40B$11.90B$17.05B
Capital expenditures$563.00M$523.00M$585.00M$728.00M$579.00M$650.00M$825.00M$924.00M$590.00M$748.00M
Free cash flow$9.46B$10.30B$7.42B$8.34B$10.80B$7.52B$8.32B$7.48B$11.31B$16.30B
Investing cash flow-$4.79B-$3.45B-$2.27B-$2.47B-$3.13B-$14.62B-$7.82B$14.36B-$16.07B-$11.98B
Financing cash flow-$7.75B-$3.43B-$5.13B-$6.47B-$8.88B$770.00M-$7.63B-$12.32B$3.39B-$9.72B
Dividends paid$4.00B$3.92B$3.81B$3.71B$3.60B$3.45B$3.22B$2.97B$2.73B$2.46B
Share repurchases$1.92B$1.15B$1.00B$1.40B$546.00M$1.58B$1.75B$2.90B$954.00M$11.00B
Stock-based compensation$894.00M$835.00M$766.00M$637.00M$635.00M$643.00M$636.00M$845.00M$638.00M$380.00M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY2.4%6.0%-0.6%-0.1%10.6%10.0%1.5%-15.2%-14.1%-6.9%
Net income growth, YoY1672.9%-91.5%23.4%-26.2%4961.0%-97.7%-1.3%17.9%-65.7%-25.4%
EPS growth, YoY1684.2%-91.6%23.6%-26.2%4830.0%-97.6%1.2%18.8%-64.7%-16.5%
Gross margin78.8%78.3%76.0%79.3%75.8%81.5%79.2%78.1%83.3%86.0%
Operating margin34.0%5.8%28.0%26.9%36.3%16.5%19.1%37.1%54.1%58.0%
Net margin28.9%1.7%20.9%16.8%22.8%0.5%24.0%24.7%17.7%44.4%
Free cash flow margin32.1%35.8%27.4%30.6%39.6%30.5%37.1%33.8%43.3%53.6%
Return on equity37.5%2.5%24.9%21.7%29.6%0.7%23.8%25.3%22.6%69.7%
Return on assets14.4%0.8%9.1%7.3%9.2%0.2%8.7%8.6%6.6%23.7%
Current ratio1.551.601.431.291.271.403.103.382.742.12
Debt to equity1.101.391.101.191.271.721.091.271.641.36

Source: XBRL data Gilead Sciences Inc. files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Get this as JSON

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Feb 27, 2013.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

GILD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
GILD$30.99B+6.5%-$3.86B-12.5%$206.55B
BMY$50.03B+4.2%$9.24B18.5%$119.25B
MRK$67.38B+4.9%$2.45B3.6%$327.41B
ABBV$66.01B+10.7%$10.34B15.7%$501.19B
AMGN$38.90B+8.2%$9.39B24.1%$237.36B
REGN$16.90B+18.6%$4.82B28.5%$95.52B
VRTX$12.95B+10.5%$3.98B30.7%$132.01B
JNJ$99.33B+7.8%$16.09B16.2%$643.09B

GILD FAQ

9 questions
  • What is GILD revenue?
    Gilead Sciences Inc. (GILD) reported $30.99B of revenue for the twelve months ended Sep 30, 2026. That is up 6.5% from the year before. Revenue for fiscal 2025 was $29.44B.
  • Is GILD profitable?
    No. Gilead Sciences Inc. reported a net loss of $3.86B for the twelve months ended Sep 30, 2026.
  • How much cash and debt does GILD have?
    Gilead Sciences Inc. reported $6.44B in cash and cash equivalents and $26.23B of debt on its most recent balance sheet in SEC filings.
  • How fast is GILD revenue growing?
    Gilead Sciences Inc.'s revenue changed +2.4% in fiscal 2025, to $29.44B. Its compound annual growth rate was +3.6% over 5 years and -1.0% over 10 years.
  • What is GILD gross margin?
    Gilead Sciences Inc.'s gross profit was $24.77B on $30.99B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 79.9%.
  • What is GILD free cash flow?
    Gilead Sciences Inc. generated $13.78B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $14.48B less capital expenditures.
  • What is GILD earnings per share?
    Diluted earnings per share were -$3.15 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did GILD last report financial results?
    The latest statements here come from Gilead Sciences Inc.'s 10-Q filed on Oct 30, 2026, covering the period ended Sep 30, 2026.
  • Where does this GILD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Gilead Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.